
Title:
Dextromethorphan
Text:
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}See also: Recreational use of dextromethorphan
Antitussive medication of the dissociative class
"DXM" redirects here. For the cricket bats, see Gunn & Moore.
Not to be confused with dextrorphan or dexamethasone.
.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}DextromethorphanClinical dataPronunciation/ˌdɛk.stroʊ.məˈθɔːrˌfæn/DEK-stroh-məth-OR-fan Trade namesRobitussin, Delsym, DM, DexAlone, Duract, othersAHFS/Drugs.comMonographMedlinePlusa682492Pregnancycategory
AU: A

Routes ofadministrationBy mouthATC codeR05DA09 (WHO) Legal statusLegal status
AU: S2 (Pharmacy medicine) 
CA: OTC 
UK: P (Pharmacy medicines) 
US: OTC,18+ and ID 
Pharmacokinetic dataBioavailability11%[1]MetabolismHepatic (liver) enzymes: major CYP2D6, minor CYP3A4, and minor CYP3A5Elimination half-life2–4 hours (extensive metabolizers); 24 hours (poor metabolizers)[2]ExcretionRenalIdentifiersshow
IUPAC name
(4bS,8aR,9S)-3-Methoxy-11-methyl-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthrene
CAS Number125-71-3 YPubChem CID5360696IUPHAR/BPS6953DrugBankDB00514 YChemSpider13109865 YUNII7355X3ROTSKEGGD03742 YChEBICHEBI:4470 NChEMBLChEMBL52440 YCompTox Dashboard (EPA)DTXSID3022908 ECHA InfoCard100.004.321 Chemical and physical dataFormulaC18H25NOMolar mass271.404 g·mol−13D model (JSmol)Interactive imageMelting point111 °C (232 °F)show
SMILES
CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc4c3cc(cc4)OC
show
InChI
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1 YKey:MKXZASYAUGDDCJ-NJAFHUGGSA-N Y
.mw-parser-output .nobold{font-weight:normal} NY (what is this?)  (verify)
Dextromethorphan, often referred to as DXM, is a medication most often used as a cough suppressant in over-the-counter cold and cough medicines. It is sold in syrup, tablet, spray, and lozenge forms.
It is in the morphinan class of medications with dissociative, and stimulant properties (at lower doses). Dextromethorphan does not have a significant affinity for the mu-opioid receptor activity typical of morphinan compounds and exerts its therapeutic effects through several other receptors.[3] In its pure form, dextromethorphan occurs as a white powder.[4]
Dextromethorphan is also used recreationally. When exceeding approved dosages, dextromethorphan acts as a dissociative hallucinogen. It has multiple mechanisms of action, including actions as a nonselective serotonin reuptake inhibitor[5] and a sigma-1 receptor agonist.[6][7] Dextromethorphan and its major metabolite, dextrorphan, also block the NMDA receptor at high doses, which produces effects similar to other dissociative anesthetics such as ketamine, nitrous oxide, and phencyclidine.
It was patented in 1949 and approved for medical use in 1953.[8]

Contents

1 Medical uses

1.1 Cough suppression
1.2 Neuropsychiatric disorders


2 Contraindications
3 Adverse effects

3.1 Neurotoxicity
3.2 Dependence and withdrawal


4 Overdose
5 Interactions
6 Pharmacology

6.1 Pharmacodynamics
6.2 Pharmacokinetics

6.2.1 Metabolism




7 Chemistry

7.1 Synthesis

7.1.1 Racemate separation
7.1.2 Traditional synthesis
7.1.3 Grewe's cyclization
7.1.4 Improved Grewe's cyclization




8 History
9 Society and culture

9.1 Marketing
9.2 Recreational use


10 Research
11 See also
12 See also
13 References
14 External links



Medical uses[edit]
  Store brand dextromethorphan cough syrup
Cough suppression[edit]
The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants.[9]

Neuropsychiatric disorders[edit]
In 2010, the FDA approved the combination drug dextromethorphan/quinidine for the treatment of pseudobulbar affect (uncontrollable laughing/crying). Dextromethorphan is the actual therapeutic agent in the combination; quinidine merely serves to inhibit the enzymatic degradation of dextromethorphan and thereby increase its circulating concentrations via inhibition of CYP2D6.[10]
In 2013, a randomized clinical trial found that dextromethorphan may reduce the overall discomfort and duration of withdrawal symptoms associated with opioid use disorder. When combined with clonidine, dextromethorphan reduced the overall time needed for withdrawal symptoms to peak by 24 hours while reducing severity of symptoms compared to clonidine alone.[11]
The combination medicine dextromethorphan/bupropion is in clinical trials by Axsome Therapeutics for major depressive disorder, with fast track designation granted by the FDA in 2017.[12] The combination showed positive results in phase 2 and phase 3 clinical trials.[13][14]

Contraindications[edit]
Because dextromethorphan can trigger a histamine release (allergic reaction), atopic children, who are especially susceptible to allergic reactions, should be administered dextromethorphan only if absolutely necessary, and only under the strict supervision of a healthcare professional.[15]

Adverse effects[edit]
Side effects of dextromethorphan at normal therapeutic doses can include:[2][9][15]

.mw-parser-output .div-col{margin-top:0.3em;column-width:30em}.mw-parser-output .div-col-small{font-size:90%}.mw-parser-output .div-col-rules{column-rule:1px solid #aaa}.mw-parser-output .div-col dl,.mw-parser-output .div-col ol,.mw-parser-output .div-col ul{margin-top:0}.mw-parser-output .div-col li,.mw-parser-output .div-col dd{page-break-inside:avoid;break-inside:avoid-column}
body rash/itching (see above)
nausea
vomiting
drowsiness
dizziness
constipation
diarrhea
sedation
confusion
nervousness
closed-eye hallucination
A rare side effect is respiratory depression.[9]

Neurotoxicity[edit]
Dextromethorphan had been thought to cause Olney's lesions when administered intravenously; however, this was later proven inconclusive, due to lack of research on humans. Tests were performed on rats, giving them 50 mg or more every day for as long as a month. Neurotoxic changes, including vacuolation, have been observed in posterior cingulate and retrosplenial cortices of rats administered other NMDA receptor antagonists such as PCP, but not with dextromethorphan.[16][17]

Dependence and withdrawal[edit]
In many documented cases[citation needed], dextromethorphan has produced psychological dependence in people who used it recreationally. It is considered less addictive than the other common weak opiate cough suppressant, codeine.[2] Since dextromethorphan also acts as a serotonin reuptake inhibitor, users report that regular recreational use over a long period of time can cause withdrawal symptoms similar to those of antidepressant discontinuation syndrome. Additionally, disturbances have been reported in sleep, senses, movement, mood, and thinking.

Overdose[edit]
Adverse effects of dextromethorphan in overdose at doses 3 to 10 times the recommended therapeutic dose:[18][failed verification]


mild nausea
restlessness
insomnia
talking fast
dilated pupils
glassy eyes
dizziness
At doses 15 to 75 times the recommended therapeutic dose:[18][failed verification][19]


hallucinations
dissociation
vomiting
delusions of grandeur
blurred vision
double vision
bloodshot eyes
dilated pupils
sweating
fever
bruxia (teeth grinding)
hypotension
hypertension
tachycardia
shallow respiration
diarrhea
urinary retention
muscle spasms
sedation
paresthesia
hypomania
slurred speech
false positives on drug screens
blackouts
inability to focus eyes
skin rash
severe itchiness
spontaneous memory recall
acute psychosis Episodic acute psychosis can occur when high doses of dextromethorphan are taken for recreational use, and an abundance of psychiatric symptoms can result, including dissociation and other PCP-like symptoms.[19]
Interactions[edit]
Dextromethorphan should not be taken with monoamine oxidase inhibitors[15] due to the potential for serotonin syndrome, which is a potentially life-threatening condition that can occur rapidly, due to a buildup of an excessive amount of serotonin in the body.
Patients who are taking dextromethorphan should exercise caution when drinking grapefruit juice or eating grapefruit, as compounds in grapefruit affect a number of drugs, including dextromethorphan, through the inhibition of the cytochrome P450 system in the liver, and can lead to excessive accumulation of the drug which both increases and prolongs effects. Grapefruit and grapefruit juices (especially white grapefruit juice, but also including other citrus fruits such as bergamot and lime, as well as a number of noncitrus fruits[20]) generally are recommended to be avoided while using dextromethorphan and numerous other medications.

Pharmacology[edit]
Pharmacodynamics[edit]

Dextromethorphan and metabolite[21][22][23][24]


Site
DXM
DXO
Species
Ref


NMDAR(MK-801)
2,120–8,945
486–906
Rat
[22]


σ1
142–652
118–481
Rat
[22]


σ2
11,060–22,864
11,325–15,582
Rat
[22]


MOR
1,280ND
420>1,000
RatHuman
[22][25]


DOR
11,500
34,700
Rat
[22]


KOR
7,000
5,950
Rat
[22]


SERT
23–40
401–484
Rat
[22]


NET
≥240
≥340
Rat
[22]


DAT
>1,000
>1,000
Rat
[22]


5-HT1A
>1,000
>1,000
Rat
[22]


5-HT1B/1D
61% at 1 μM
54% at 1 μM
Rat
[22]


5-HT2A
>1,000
>1,000
Rat
[22]


α1
>1,000
>1,000
Rat
[22]


α2
60% at 1 μM
>1,000
Rat
[22]


β
>1,000
35% at 1 μM
Rat
[22]


D2
>1,000
>1,000
Rat
[22]


H1
>1,000
95% at 1 μM
Rat
[22]


mAChRs
>1,000
100% at 1 μM
Rat
[22]


nAChRs
700–8,900(IC50)
1,300–29,600(IC50)
Rat
[22]


VDSCs
>50,000 (IC50)
ND
Rat
[26][27]


Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.

Dextromethorphan has been found to possess the following actions (<1 μM) using rat tissues:[22][28]

Uncompetitive antagonist of the NMDA receptor via the MK-801/PCP site[28]
SERT and NET blocker (cf. serotonin–norepinephrine reuptake inhibitor)
Sigma σ1 receptor agonist
Negative allosteric modulator of nicotinic acetylcholine receptors
Ligand of the serotonin 5-HT1B/1D, histamine H1, α2-adrenergic, and muscarinic acetylcholine receptors
Dextromethorphan is a prodrug of dextrorphan, which is the actual mediator of most of its dissociative effects through acting as a more potent NMDA receptor antagonist than dextromethorphan itself.[29] What role, if any, (+)-3-methoxymorphinan, dextromethorphan's other major metabolite, plays in its effects is not entirely clear.[30]

Pharmacokinetics[edit]
Following oral administration, dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood–brain barrier.[citation needed]
At therapeutic doses, dextromethorphan acts centrally (meaning that it acts on the brain) as opposed to locally (on the respiratory tract). It elevates the threshold for coughing, without inhibiting ciliary activity. Dextromethorphan is rapidly absorbed from the gastrointestinal tract and converted into the active metabolite dextrorphan in the liver by the cytochrome P450 enzyme CYP2D6. The average dose necessary for effective antitussive therapy is between 10 and 45 mg, depending on the individual. The International Society for the Study of Cough recommends "an adequate first dose of medication is 60 mg in the adult and repeat dosing should be infrequent rather than qds recommended."[31]
Dextromethorphan has an elimination half-life of approximately 4 hours in individuals with an extensive metabolizer phenotype; this is increased to approximately 13 hours when dextromethorphan is given in combination with quinidine.[24] The duration of action after oral administration is about three to eight hours for dextromethorphan hydrobromide, and 10 to 12 hours for dextromethorphan polistirex. Around one in 10 of the Caucasian population has little or no CYP2D6 enzyme activity, leading to long-lived high drug levels.[31]

Metabolism[edit]
  Main metabolic pathways of dextromethorphan degradation, which are catalyzed by cytochrome P450 monooxygenases (CYP3A4 and CYP2D6) and UDP-glucuronosyl-transferase (UGT).[32]
The first pass through the hepatic portal vein results in some of the drug being metabolized by O-demethylation into an active metabolite of dextromethorphan called dextrorphan, the 3-hydroxy derivative of dextromethorphan. The therapeutic activity of dextromethorphan is believed to be caused by both the drug and this metabolite. Dextromethorphan also undergoes N-demethylation (to 3-methoxymorphinan or MEM),[33] and partial conjugation with glucuronic acid and sulfate ions. Hours after dextromethorphan therapy, (in humans) the metabolites (+)-3-hydroxy-N-methylmorphinan, (+)-3-morphinan, and traces of the unchanged drug are detectable in the urine.[15]
A major metabolic catalyst involved is the cytochrome P450 enzyme known as 2D6, or CYP2D6. A significant portion of the population has a functional deficiency in this enzyme and are known as poor CYP2D6 metabolizers. O-demethylation of dextromethorphan to dextrorphan contributes to at least 80% of the dextrorphan formed during dextromethorphan metabolism.[33] As CYP2D6 is a major metabolic pathway in the inactivation of dextromethorphan, the duration of action and effects of dextromethorphan can be increased by as much as three times in such poor metabolizers.[34] In one study on 252 Americans, 84.3% were found to be "fast" (extensive) metabolizers, 6.8% to be "intermediate" metabolizers, and 8.8% were "slow" metabolizers of dextromethorphan.[35] A number of alleles for CYP2D6 are known, including several completely inactive variants. The distribution of alleles is uneven amongst ethnic groups.
A large number of medications are potent inhibitors of CYP2D6. Some types of medications known to inhibit CYP2D6 include certain SSRIs and tricyclic antidepressants, some antipsychotics, and the commonly available antihistamine diphenhydramine. Therefore, the potential of interactions exists between dextromethorphan and medications that inhibit this enzyme, particularly in slow metabolizers.
Dextromethorphan is also metabolized by CYP3A4. N-demethylation is primarily accomplished by CYP3A4, contributing to at least 90% of the MEM formed as a primary metabolite of dextromethorphan.[33]
A number of other CYP enzymes are implicated as minor pathways of dextromethorphan metabolism. CYP2B6 is more effective than CYP3A4 at N-demethylation of dextromethorphan, but since the average individual has a much lower CYP2B6 content in the liver compared to CYP3A4, most N-demethylation of dextromethorphan is catalyzed by CYP3A4.[33]

Chemistry[edit]
Dextromethorphan is the dextrorotatory enantiomer of levomethorphan, which is the methyl ether of levorphanol, both opioid analgesics. It is named according to IUPAC rules as (+)-3-methoxy-17-methyl-9α,13α,14α-morphinan. As its pure form, dextromethorphan occurs as an odorless, opalescent white powder. It is freely soluble in chloroform and insoluble in water; the hydrobromide salt is water-soluble up to 1.5 g/100 mL at 25 °C.[36] Dextromethorphan is commonly available as the monohydrated hydrobromide salt, however some newer extended-release formulations contain dextromethorphan bound to an ion-exchange resin based on polystyrene sulfonic acid. Dextromethorphan's specific rotation in water is +27.6° (20 °C, Sodium D-line).[citation needed]

Synthesis[edit]
Several routes exist for the synthesis of Dextromethorphan. Even though many of the syntheses have been known since the middle of the 20th century, researchers are still working today to further develop the synthesis of Dextromethorphan and, for example, to make it more environmentally friendly.
This includes the synthesis by means of ionic liquids.[37]

Racemate separation[edit]
Since only one of the stereoisomers has the desired effect, the separation of a racemic mixture of hydroxy N- methyl morphinan using tartaric acid and subsequent methylation of the hydroxyl group is a suitable method. By using (D)-tartrate, the (+)-isomer remains as the product.


This synthetic pathway was patented by Roche in 1950.

Traditional synthesis[edit]
The traditional synthetic route uses Raney nickel and has been further improved over time, for example by the use of ibuprofen and ACl3.


Overall, it is a cost-effective method with moderate reaction conditions that is easy to handle and suitable for industrial production.[37]

Grewe's cyclization[edit]

Grewe's cyclization is easier to handle in terms of the chemicals used, produces higher yields and higher purity of the product.[38]

Improved Grewe's cyclization[edit]
Formylation prior to cyclization avoids ether cleavage as a side reaction and yields higher than without N-substitution or N-methylation. In this example, the purification was done by formation of a brucine salt.[37]


This process has also been patented by Roche.

History[edit]
The racemic parent compound racemorphan was first described in a Swiss and US patent application from Hoffmann-La Roche in 1946 and 1947, respectively; a patent was granted in 1950. A resolution of the two isomers of racemorphan with tartaric acid was published in 1952,[39] and dextromethorphan was successfully tested in 1954 as part of US Navy and CIA-funded research on nonaddictive substitutes for codeine.[40] Dextromethorphan was approved by the FDA in 1958 as an over-the-counter antitussive.[39] As had been initially hoped, dextromethorphan was a solution for some of the problems associated with the use of codeine phosphate as a cough suppressant, such as sedation and opiate dependence, but like the dissociative anesthetics phencyclidine and ketamine, dextromethorphan later became associated with nonmedical use.[39][41]
During the 1960s and 1970s, dextromethorphan became available in an over-the-counter tablet form by the brand name Romilar. In 1973, Romilar was taken off the shelves after a burst in sales because of frequent misuse. A few years later, products with an unpleasant taste were introduced (such as Robitussin, Vicks-44, and Dextrotussion), but later the same manufacturers began producing products with a better taste.[41] The advent of widespread internet access in the 1990s allowed users to rapidly disseminate information about dextromethorphan, and online discussion groups formed around use and acquisition of the drug. As early as 1996, dextromethorphan hydrobromide powder could be purchased in bulk from online retailers, allowing users to avoid consuming dextromethorphan in syrup preparations.[39]
FDA panels considered moving dextromethorphan to prescription status due to its potential for abuse, but voted against the recommendation in September 2010, citing lack of evidence that making it prescription-only would curb abuse.[42] Some states have restricted the sale of dextromethorphan to adults or put other restrictions on its purchase in place, similar to those for pseudoephedrine. As of January 1, 2012, dextromethorphan is prohibited for sale to minors in the State of California and in the State of Oregon as of January 1, 2018, except with a doctor's prescription.[43] Several other states have also begun regulating sales of dextromethorphan to minors.
In Indonesia, the National Agency of Drug and Food Control (BPOM-RI) prohibited single-component dextromethorphan drug sales with or without prescription. Indonesia is the only country in the world that makes single-component dextromethorphan illegal even by prescription[44] and violators may be prosecuted by law. National Anti-Narcotics Agency (BNN RI) has even threatened to revoke pharmacies' and drug stores' licenses if they still stock dextromethorphan, and will notify the police for criminal prosecution.[45] As a result of this regulation, 130 medications have been withdrawn from the market, but those containing multicomponent dextromethorphan can still be sold over the counter.[46][47]

Society and culture[edit]
Marketing[edit]
It may be used in generic labels and store brands, Benylin DM, Mucinex DM, Camydex-20 tablets, Robitussin, NyQuil, Dimetapp, Vicks, Coricidin, Delsym, TheraFlu, Charcoal D, Cinfatós and others. It has been used in counterfeit medications.[48]

Recreational use[edit]
Main article: Recreational use of dextromethorphan
  Dextromethorphan gel capsules
Over-the-counter preparations containing dextromethorphan have been used in manners inconsistent with their labeling, often as a recreational drug.[41] At doses much higher than medically recommended, dextromethorphan and its major metabolite, dextrorphan, acts as an NMDA receptor antagonist, which produces dissociative hallucinogenic states somewhat similar to ketamine and phencyclidine.[49] It may produce distortions of the visual field – feelings of dissociation, distorted bodily perception, excitement, and a loss of sense of time. Some users report stimulant-like euphoria, particularly in response to music. Dextromethorphan usually provides its recreational effects in a non-linear fashion, so that they are experienced in significantly varied stages. These stages are commonly referred to as "plateaus". These plateaus are numbered from one to four, with the first having the mildest effects to fourth being the most intense. Each plateau is said to come with different related effects and experiences.[50] The first plateau is said to induce music euphoria and mild stimulation, likened to that of MDMA. The second plateau is likened to the state of being drunk and high at the same time, featuring euphoria, sedation and minor hallucinations. The third plateau induces a significant dissociative state which can often cause anxiety in users. Reaching the fourth plateau is said to cause extreme sedation and a significant hallucinatory state as well as complete dissociation from reality. Teens tend to have a higher likelihood to use dextromethorphan-related drugs as they are easier to access, and an easier way to cope with psychiatric disorders.[51]

Research[edit]
The combination drug dextromethorphan/quinidine (AVP-923),[52][53] traditionally used to treat pseudobulbar affect, is under investigation for the treatment of a variety of other neurological and neuropsychiatric conditions including agitation associated with Alzheimer's disease and major depressive disorder.[10][54] Dextromethorphan is currently being studied for use in treatment-resistant depression,[55][56][57][58] although early studies have yielded mixed results.[59] Serotonin syndrome may result from the combined use of dextromethorphan and serotonergic antidepressants such as SSRIs or MAOIs,[60] but further research is needed to determine whether doses of dextromethorphan beyond those normally used therapeutically are needed to produce this effect.[61]

See also[edit]
List of investigational antidepressants
List of investigational antipsychotics
See also[edit]
Cough syrup
Noscapine
Codeine; Pholcodine
Dimemorfan
Racemorphan; Dextrorphan; Levorphanol
Butamirate
Pentoxyverine
Tipepidine
Cloperastine
Levocloperastine
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Kukanich B, Papich MG (October 2004). "Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs". Journal of Veterinary Pharmacology and Therapeutics. 27 (5): 337–41. doi:10.1111/j.1365-2885.2004.00608.x. PMID 15500572.

^ Jump up to: a b c "Balminil DM, Benylin DM (dextromethorphan) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 15 April 2014.

^ Taylor, Charles P.; Traynelis, Stephen F.; Siffert, Joao; Pope, Laura E.; Matsumoto, Rae R. (August 2016). "Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use". Pharmacology & Therapeutics. 164: 170–182. doi:10.1016/j.pharmthera.2016.04.010. PMID 27139517 – via Elsevier ScienceDirecr.

^ "Reference Tables: Description and Solubility - D". Archived from the original on 2017-07-04. Retrieved 2011-05-06.

^ Schwartz AR, Pizon AF, Brooks DE (September 2008). "Dextromethorphan-induced serotonin syndrome". Clinical Toxicology. 46 (8): 771–3. doi:10.1080/15563650701668625. PMID 19238739. S2CID 37817922.

^ Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP,  et al. (May 2007). "Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats". Neurochemistry International. 50 (6): 791–9. doi:10.1016/j.neuint.2007.01.008. PMID 17386960. S2CID 43230896.

^ Shin EJ, Nah SY, Kim WK, Ko KH, Jhoo WK, Lim YK,  et al. (April 2005). "The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan". British Journal of Pharmacology. 144 (7): 908–18. doi:10.1038/sj.bjp.0705998. PMC 1576070. PMID 15723099.

^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 527. ISBN 9783527607495.

^ Jump up to: a b c Rossi, S, ed. (2013). Australian Medicines Handbook. Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.[page needed]

^ Jump up to: a b Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR (March 2016). "Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders". Pharmacology & Therapeutics. 159: 1–22. doi:10.1016/j.pharmthera.2016.01.016. PMID 26826604.

^ Malek A, Amiri S, Habibi Asl B (2013). "The therapeutic effect of adding dextromethorphan to clonidine for reducing symptoms of opioid withdrawal: a randomized clinical trial". ISRN Psychiatry. 2013: 546030. doi:10.1155/2013/546030. PMC 3706070. PMID 23864983.

^ Inc, Axsome Therapeutics (2017-02-14). "Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression". GlobeNewswire News Room. Retrieved 2019-12-22.

^ "Dextromethorphan/bupropion combo is remarkably fast-acting antidepressant". www.mdedge.com. Retrieved 2019-12-22.

^ "Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder". Axsome Therapeutics, Inc. Retrieved 2019-12-22.

^ Jump up to: a b c d "Dextromethorphan". National Highway Traffic Safety Administration (NHTSA). Archived from the original on 2008-08-01.

^ Olney JW, Labruyere J, Price MT (June 1989). "Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs". Science. 244 (4910): 1360–2. Bibcode:1989Sci...244.1360O. doi:10.1126/science.2660263. PMID 2660263.

^ Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL (July 2007). "Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain". Neurotoxicology. 28 (4): 813–8. doi:10.1016/j.neuro.2007.03.009. PMID 17573115.

^ Jump up to: a b "Teen Drug Abuse: Cough Medicine and DXM (Dextromethorphan)". webmd. Archived from the original on 2017-11-21.

^ Jump up to: a b Martinak B, Bolis RA, Black JR, Fargason RE, Birur B (September 2017). "Dextromethorphan in Cough Syrup: The Poor Man's Psychosis". Psychopharmacology Bulletin. 47 (4): 59–63. PMC 5601090. PMID 28936010.

^ "Inhibitors of CYP3A4". ganfyd.org. Archived from the original on 2017-07-20. Retrieved 23 August 2013.

^ Roth, BL; Driscol, J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.

^ Jump up to: a b c d e f g h i j k l m n o p q r s t u Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR (March 2016). "Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders" (PDF). Pharmacology & Therapeutics. 159: 1–22. doi:10.1016/j.pharmthera.2016.01.016. PMID 26826604.

^ Werling LL, Keller A, Frank JG, Nuwayhid SJ (October 2007). "A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder". Experimental Neurology. 207 (2): 248–57. doi:10.1016/j.expneurol.2007.06.013. PMID 17689532. S2CID 38476281.

^ Jump up to: a b Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR (August 2016). "Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use". Pharmacology & Therapeutics. 164: 170–82. doi:10.1016/j.pharmthera.2016.04.010. PMID 27139517.

^ Raynor K, Kong H, Mestek A, Bye LS, Tian M, Liu J,  et al. (January 1995). "Characterization of the cloned human mu opioid receptor". The Journal of Pharmacology and Experimental Therapeutics. 272 (1): 423–8. PMID 7815359.

^ Lee JH, Shin EJ, Jeong SM, Lee BH, Yoon IS, Lee JH,  et al. (June 2007). "Effects of dextrorotatory morphinans on brain Na+ channels expressed in Xenopus oocytes". European Journal of Pharmacology. 564 (1–3): 7–17. doi:10.1016/j.ejphar.2007.01.088. PMID 17346698.

^ Gao XF, Yao JJ, He YL, Hu C, Mei YA (2012). "Sigma-1 receptor agonists directly inhibit Nav1.2/1.4 channels". PLOS ONE. 7 (11): e49384. Bibcode:2012PLoSO...749384G. doi:10.1371/journal.pone.0049384. PMC 3489664. PMID 23139844.

^ Jump up to: a b Burns JM, Boyer EW (2013). "Antitussives and substance abuse". Substance Abuse and Rehabilitation. 4: 75–82. doi:10.2147/SAR.S36761. PMC 3931656. PMID 24648790.

^ Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (March 1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research. 821 (2): 516–9. doi:10.1016/S0006-8993(99)01125-7. PMID 10064839. S2CID 22762264.

^ Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI (April 1997). "Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1". Biopharmaceutics & Drug Disposition. 18 (3): 227–40. doi:10.1002/(SICI)1099-081X(199704)18:3<227::AID-BDD18>3.0.CO;2-L. PMID 9113345.

^ Jump up to: a b Morice AH. "Cough". International Society for the Study of Cough. Archived from the original on 2017-05-09.

^ Strauch K, Lutz U, Bittner N, Lutz WK (August 2009). "Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles". Food and Chemical Toxicology. 47 (8): 1928–35. doi:10.1016/j.fct.2009.05.004. PMID 19445995.

^ Jump up to: a b c d Yu A, Haining RL (November 2001). "Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?". Drug Metabolism and Disposition. 29 (11): 1514–20. PMID 11602530.

^ Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA (September 1996). "The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans". Clinical Pharmacology and Therapeutics. 60 (3): 295–307. doi:10.1016/S0009-9236(96)90056-9. PMID 8841152. S2CID 10147669.

^ Woodworth JR, Dennis SR, Moore L, Rotenberg KS (February 1987). "The polymorphic metabolism of dextromethorphan". Journal of Clinical Pharmacology. 27 (2): 139–43. doi:10.1002/j.1552-4604.1987.tb02174.x. PMID 3680565. S2CID 37950361.

^ "Dextromethorphan (PIM 179)". www.inchem.org. Archived from the original on 2017-03-10. Retrieved 2018-03-24.

^ Jump up to: a b c Sethi, Madhuresh Kumar (2018-06-11). "Preparation of Morphine Derivatives Using Ionic Liquids". Archives of Organic and Inorganic Chemical Sciences. 3 (2). doi:10.32474/AOICS.2018.03.000156.

^ MEUZELAAR, G. J.; NEELEMAN, E.; MAAT, L.; SHELDON, R. A. (2010-06-17). "ChemInform Abstract: A Novel Synthesis of Substituted 1-Benzyloctahydroisoquinolines by Acid-Catalyzed Cyclization of N-[2-(Cyclohex-1-enyl)ethyl]-N-styrylformamides". ChemInform. 30 (5): no. doi:10.1002/chin.199905129. ISSN 0931-7597.

^ Jump up to: a b c d Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID 24678061.

^ "Memorandum for the Secretary of Defense" (PDF). Archived (PDF) from the original on 2017-09-16. Retrieved 2013-07-28.

^ Jump up to: a b c "Dextromethorphan (DXM)". Cesar.umd.edu. Archived from the original on 2018-01-06. Retrieved 2013-07-28.

^ Nordqvist C. FDA panel: cough meds should stay over the counter. Sept. 14, 2010. Medical News Today Website. http://www.medicalnewstoday.com/articles/201227.php. Accessed May 18, 2020. 

^ "Senate Bill No. 514" (PDF). An act to add Sections 11110 and 11111 to the Health and Safety Code, relating to nonprescription drugs. State of California, Legislative Counsel. Archived (PDF) from the original on 2018-03-08.

^ http://nasional.news.viva.co.id/news/read/506418-bpom-tetap-batalkan-izin-edar-obat-dekstrometorfan Archived 2015-05-28 at the Wayback Machine[full citation needed]

^ "SINDOnews | Berita Daerah Dan Provinsi Di Indonesia". daerah.sindonews.com (in Indonesian). Retrieved 2017-12-10.[dead link]

^ "Pimpinan dan Apoteker Penanggung Jawab" (PDF). Archived from the original (PDF) on 2017-08-10.

^ "Badan Pengawas Obat dan Makanan - Republik Indonesia". www.pom.go.id. Archived from the original on 2017-02-03. Retrieved 2017-12-10.

^ "Fake drugs: the global industry putting your life at risk". Mosaic. 30 October 2018. Retrieved 13 December 2018.

^ "Dextromethorphan" (PDF). Drugs and Chemicals of Concern. Drug Enforcement Administration. August 2010. Archived from the original (PDF) on 2012-10-16.

^ Giannini AJ (1997). Drugs of abuse (2nd ed.). Los Angeles: Practice Management Information Corp. ISBN 1570660530.[page needed]

^ Ackerman, Sarah C.; Hammel, John L.; Brunette, Mary F. (2010-12-20). "Dextromethorphan Abuse and Dependence in Adolescents". Journal of Dual Diagnosis. 6 (3–4): 266–278. doi:10.1080/15504263.2010.537515. S2CID 70666093.

^ Olney N, Rosen H (April 2010). "AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain". IDrugs : The Investigational Drugs Journal. 13 (4): 254–65. PMID 20373255.

^ Khoury R, Marx C, Mirgati S, Velury D, Chakkamparambil B, Grossberg GT (May 2021). "AVP-786 as a promising treatment option for Alzheimer's Disease including agitation". Expert Opinion on Pharmacotherapy. 22 (7): 783–795. doi:10.1080/14656566.2021.1882995. PMID 33615952. S2CID 231987025.

^ Murrough, James W.; Wade, Elizabeth; Sayed, Sehrish; Ahle, Gabriella; Kiraly, Drew D.; Welch, Alison; Collins, Katherine A.; Soleimani, Laili; Iosifescu, Dan V.; Charney, Dennis S. (2017). "Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial". Journal of Affective Disorders. 218: 277–283. doi:10.1016/j.jad.2017.04.072. ISSN 0165-0327. PMID 28478356.

^ Johns Hopkins University (2020-04-24). "An Open-Label Tolerance Study of Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder". {{cite journal}}: Cite journal requires |journal= (help)

^ Lauterbach, Edward C. (2016-08-15). "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule". Psychopharmacology Bulletin. 46 (2): 53–58. ISSN 0048-5764. PMC 5044468. PMID 27738380.

^ Lauterbach, Edward C. (2011). "Dextromethorphan as a potential rapid-acting antidepressant". Medical Hypotheses. 76 (5): 717–719. doi:10.1016/j.mehy.2011.02.003. ISSN 1532-2777. PMID 21367535.

^ Nguyen, Linda; Lucke-Wold, Brandon P.; Logsdon, Aric F.; Scandinaro, Anna L.; Huber, Jason D.; Matsumoto, Rae R. (2016-09-28). "Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice". NeuroReport. 27 (14): 1004–1011. doi:10.1097/WNR.0000000000000646. ISSN 0959-4965. PMC 5020901. PMID 27580401.

^ Nofziger, Jill L.; Paxos, Chris; Emshoff, Jessica; Mullen, Chanda (2019-03-01). "Evaluation of dextromethorphan with select antidepressant therapy for the treatment of depression in the acute care psychiatric setting". The Mental Health Clinician. 9 (2): 76–81. doi:10.9740/mhc.2019.03.076. ISSN 2168-9709. PMC 6398352. PMID 30842914.

^ Dy, Prudence; Arcega, Victor; Ghali, Wael; Wolfe, Winifred (2017-08-07). "Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan". BMJ Case Reports. 2017: bcr–2017–221486. doi:10.1136/bcr-2017-221486. ISSN 1757-790X. PMC 5747823. PMID 28784915.

^ Schwartz, Anna R.; Pizon, Anthony F.; Brooks, Daniel E. (2008). "Dextromethorphan-induced serotonin syndrome". Clinical Toxicology (Philadelphia, Pa.). 46 (8): 771–773. doi:10.1080/15563650701668625. ISSN 1556-3650. PMID 19238739. S2CID 37817922.


External links[edit]



Wikimedia Commons has media related to Dextromethorphan.

U.S. National Library of Medicine: Drug Information Portal – Dextromethorphan
Nuedexta (dextromethorphan hydrobromide and quinidine sulfate): Prescribing Information (Original Approval Date FDA: October 29, 2010)
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}show.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteCough and cold preparations (R05)Expectorants
Althea root
Antimony pentasulfide
Creosote
Guaiacolsulfonate
Guaifenesin (+ oxomemazine)
Ipecacuanha (Syrup of ipecac)
Levoverbenone
Potassium iodide
Senega
Tyloxapol
Ammonium Chloride
Mucolytics
Acetylcysteine#
Ambroxol
Bromhexine
Carbocisteine
Domiodol
Dornase alfa
Eprazinone
Erdosteine
Letosteine
Mannitol
Mesna
Neltenexine
Sobrerol
Stepronin
Cough suppressantsOpium alkaloids,opioids,and derivatives
Acetyldihydrocodeine
Benzylmorphine
Butorphanol
Codeine#
Dextromethorphan
Dihydrocodeine
Dimemorfan
Droxypropine
Ethylmorphine
Heroin
Hydrocodone
Hydromorphone
Isoaminile
Laudanum
Levomethadone
Levopropoxyphene
Methadone
Nicocodeine
Nicodicodeine
Normethadone
Noscapine
Pholcodine
Thebacon
Tipepidine
Other
Alloclamide
Benzonatate
Benproperine
Bibenzonium bromide
Butamirate
Clobutinol
Clofedanol
Cloperastine
Diphenhydramine
Dibunate
Dimethoxanate
Dropropizine
Fedrilate
Fominoben
Glaucine
Levodropropizine
Meprotixol
Moguisteine
Morclofone
Nepinalone
Oxolamine
Oxeladin
Pentoxyverine
Pipazetate
Prenoxdiazine
Piperidione
Zipeprol

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

showRecreational uses
showvteRecreational drug useMajor recreational drugsDepressants
Barbiturates
Benzodiazepines
Carbamates
Ethanol (alcohol)
Alcoholic drinks
Beer
Wine
Gabapentinoids
GHB
Inhalants
Medical
Nitrous oxide (recreational use)
Hazardous solvents
contact adhesives
Gasoline
nail polish remover
Paint thinner
Other
Freon
Kava
Nonbenzodiazepines
Quinazolinones
Opioids
Buprenorphine
Suboxone
Subutex
Codeine
Desomorphine
Krokodil
Dextropropoxyphene
Darvocet
Darvon
Fentanyl
Diamorphine
Heroin
Hydrocodone
Hydromorphone
Dilaudid
Methadone
Mitragyna speciosa
Kratom
Morphine
Opium
Oxycodone
/paracetamol
Tramadol
Stimulants
Amphetamine
Arecoline
Areca
Betel
Caffeine
Coffee
Energy drinks
Tea
Cathinone
Khat
Cocaine
Coca
Crack
Ephedrine
Ephedra
MDPV
Mephedrone
Methamphetamine
Methylone
Methylphenidate
Modafinil
Nicotine
Tobacco
Theobromine
Cocoa
Chocolate
Entactogens
2C series
6-APB
Benzofury
AMT
MDA
MDMA
Ecstasy
HallucinogensPsychedelics
Bufotenin
Psychoactive toads
Vilca
Yopo
DMT
Ayahuasca
LSA
LSD-25
Mescaline
Peruvian torch
Peyote
San Pedro
Psilocybin / Psilocin
Psilocybin mushrooms
Dissociatives
DXM (recreational use)
Glaucine
Inhalants
Nitrous oxide (recreational use)
alkyl nitrites
poppers
amyl nitrite
Ketamine
MXE
Muscimol
Amanita muscaria
PCP
Salvinorin A
Salvia divinorum
Deliriants
Atropine and Scopolamine
Atropa belladonna
Datura
Hyoscyamus niger
Mandragora officinarum
Dimenhydrinate
Diphenhydramine
Cannabinoids
THC
Cannabis (Marijuana)
Hashish
Hash oil
Neocannabinoid / synthetic cannabinoids
JWH-018
APICA
APINACA
Spice
Oneirogens
Calea zacatechichi
Silene capensis
Club drugs
Cocaine
Quaaludes
MDMA (Ecstasy)
Nitrous oxide (recreational use)
Poppers
Drug cultureCannabis culture
420
Cannabis cultivation
Cannabis rights leaders
Cannabis smoking
Cannabis Social Club
Head shop
Legal history of cannabis in the United States
Legality of cannabis
Marijuana Policy Project
Medical cannabis
NORML
Cannabis and religion
Stoner film
Coffee culture
Coffee break
Coffeehouse
Latte art
Teahouse
Drinking culture
Bartending
Beer culture
Beer festival
Binge drinking
Diethyl ether
Drinking games
Drinking song
Happy hour
Hip flask
Nightclub
Pub
Pub crawl
Sommelier
Sports bar
Tailgate party
Wine bar
Wine tasting
Psychedelia
Psychonautics
Art
Drug
Era
Experience
Literature
Music
Microdosing
Therapy
Smoking culture
Cigarette card
Fashion cigarettes
Cloud-chasing
Loosie
Smokeasy
Smoking fetishism
Tobacco smoking
Other
Club drug
Counterculture of the 1960s
Dance party
Drug paraphernalia
Drug tourism
Entheogen
Hippie
Needle sharing
Nootropic
Party and play
Poly drug use
Rave
Religion and drugs
Self-medication
Sex and drugs
Whoonga
Drug production and tradeDrug production
Coca production in Colombia
Drug precursors
Opium production in Afghanistan
Rolling meth lab
Drug trade
Illegal drug trade
Colombia
Darknet market
Pharmaceutical distribution
Beer shop
Cannabis shop
Liquor store
Liquor license
Issues with drug use
Abuse
Addiction
Date rape drug
Dependence
Opioid replacement therapy
Prevention
Rehabilitation
Responsible use
Driving impaired
Drug checking
Reagent testing
Drug harmfulness
Effects of cannabis
Drug-related crime
Fetal alcohol spectrum disorder
Long-term effects of cannabis
Neurotoxicity
Overdose
Passive smoking
of tobacco or other substances
Legality of drug useInternational
International Drug Control Conventions
1961 Narcotic Drugs
1971 Psychotropic Substances
1988 Drug Trafficking
Other treaties addressing drugs
Law of the Sea Convention
Convention Against Doping
Council of the European Union decisions on designer drugs
State level
Drug policy
Decriminalization
Prohibition
Supply reduction
Policy reform
Demand reduction
Drug Policy Alliance
Harm reduction
Law Enforcement Action Partnership
Liberalization
Latin America
Students for Sensible Drug Policy
Transform Drug Policy Foundation
Drug policyby country
Australia
Canada
Germany
India
Netherlands
Portugal
Slovakia
Soviet Union
Sweden
Switzerland
United States
Just Say No
Office of National Drug Control Policy
School district drug policies
California
Colorado
Maryland
Virginia
Other
Arguments for and against drug prohibition
Capital punishment for drug trafficking
Cognitive liberty
Designer drug
Drug court
Drug possession
Drug test
Narc
Politics of drug abuse
War on drugs
Mexican drug war
Plan Colombia
Philippine drug war
Zero tolerance
Lists of countries by...
Alcohol legality
Alcohol consumption
Anabolic steroid legality
Cannabis legality
Annual use
Lifetime use
Tobacco consumption
Cocaine legality
Cocaine use
Methamphetamine legality
Opiates use
Psilocybin mushrooms legality
Salvia legality

showvteHallucinogensPsychedelics(5-HT2Aagonists)Benzofurans
2C-B-FLY
2CBFly-NBOMe
5-MeO-BFE
5-MeO-DiBF
Bromo-DragonFLY
F-2
F-22
TFMFly
Lyserg‐amides
1B-LSD
1cP-LSD
1P-ETH-LAD
1P-LSD
1cP-AL-LAD
1cP-MiPLA
1V-LSD
2-Butyllysergamide
3-Pentyllysergamide
AL-LAD
ALD-52
BU-LAD
Diallyllysergamide
Dimethyllysergamide
ECPLA
Ergometrine
ETH-LAD
IP-LAD
LAE-32
LAMPA
LPD-824
LSA
LSD
LSD-Pip
LSH
LSM-775
LSZ
Methylergometrine
MIPLA
Methysergide
MLD-41
PARGY-LAD
PRO-LAD
Phenethyl‐amines2C-x
2C-B
2C-B-AN
2C-Bn
2C-Bu
2C-C
2C-CN
2C-CP
2C-D
2C-E
2C-EF
2C-F
2C-G
2C-G-1
2C-G-2
2C-G-3
2C-G-4
2C-G-5
2C-G-6
2C-G-N
2C-H
2C-I
2C-iP
2C-N
2C-NH2
2C-O
2C-O-4
2C-P
2C-Ph
2C-SE
2C-T
2C-T-2
2C-T-3
2C-T-4
2C-T-5
2C-T-6
2C-T-7
2C-T-8
2C-T-9
2C-T-10
2C-T-11
2C-T-12
2C-T-13
2C-T-14
2C-T-15
2C-T-16
2C-T-17
2C-T-18
2C-T-19
2C-T-20
2C-T-21
2C-T-22
2C-T-22.5
2C-T-23
2C-T-24
2C-T-25
2C-T-27
2C-T-28
2C-T-30
2C-T-31
2C-T-32
2C-T-33
2C-TFE
2C-TFM
2C-YN
2C-V
    25x-NBx25x-NB
25B-NB
25C-NB
25x-NB3OMe
25B-NB3OMe
25C-NB3OMe
25D-NB3OMe
25E-NB3OMe
25H-NB3OMe
25I-NB3OMe
25N-NB3OMe
25P-NB3OMe
25T2-NB3OMe
25T4-NB3OMe
25T7-NB3OMe
25TFM-NB3OMe
25x-NB4OMe
25B-NB4OMe
25C-NB4OMe
25D-NB4OMe
25E-NB4OMe
25H-NB4OMe
25I-NB4OMe
25N-NB4OMe
25P-NB4OMe
25T2-NB4OMe
25T4-NB4OMe
25T7-NB4OMe
25TFM-NB4OMe
25x-NBF
25B-NBF
25C-NBF
25D-NBF
25E-NBF
25H-NBF
25I-NBF
25P-NBF
25T2-NBF
25T7-NBF
25TFM-NBF
25x-NBMD
25B-NBMD
25C-NBMD
25D-NBMD
25E-NBMD
25F-NBMD
25H-NBMD
25I-NBMD
25P-NBMD
25T2-NBMD
25T7-NBMD
25TFM-NBMD
25x-NBOH
25B-NBOH
25C-NBOH
25CN-NBOH
25D-NBOH
25E-NBOH
25F-NBOH
25H-NBOH
25I-NBOH
25P-NBOH
25T2-NBOH
25T7-NBOH
25TFM-NBOH
25x-NBOMe
25B-NBOMe
25C-NBOMe
25CN-NBOMe
25D-NBOMe
25E-NBOMe
25F-NBOMe
25G-NBOMe
25H-NBOMe
25I-NBOMe
25iP-NBOMe
25N-NBOMe
25P-NBOMe
25T-NBOMe
25T2-NBOMe
25T4-NBOMe
25T7-NBOMe
25TFM-NBOMe
Atypical structures
25B-N1POMe
25B-NAcPip
25B-NB23DM
25B-NB25DM
25C-NBCl
25C-NBOEt
25C-NBOiPr
25I-N2Nap1OH
25I-N3MT2M
25I-N4MT3M
25I-NB34MD
25I-NBAm
25I-NBBr
25I-NBMeOH
25I-NBTFM
2CBCB-NBOMe
2CBFly-NBOMe
4-EA-NBOMe
5-APB-NBOMe
5MT-NBOMe
C30-NBOMe
DOB-NBOMe
DOI-NBOMe
FECIMBI-36
MDPEA-NBOMe
NBOMe-escaline
NBOMe-mescaline
ZDCM-04
25x-NMx
25B-NMe7BF
25B-NMe7BT
25B-NMe7Box
25B-NMe7DHBF
25B-NMe7Ind
25B-NMe7Indz
25B-NMePyr
25I-NMe7DHBF
25I-NMeFur
25I-NMeTHF
25I-NMeTh

3C-x
3C-AL
3C-BZ
3C-DFE
3C-E
3C-MAL
3C-P
4C-x
4C-B
4C-C
4C-D
4C-E
4C-I
4C-N
4C-P
4C-T-2
DOx
DOT
DOB
DOC
DOEF
DOET
DOF
DOI
DOiPR
DOM
DON
DOPR
DOTFM
MEM
HOT-x
HOT-2
HOT-7
HOT-17
MDxx
DMMDA
DMMDA-2
Lophophine
MDA
MDAI
MDBZ
MDMA
MMDA
MMDA-2
MMDA-3a
MMDMA
Mescaline (subst.)
2-Bromomescaline
3-TE
4-TE
3-TM
4-TM
Allylescaline
Asymbescaline
Buscaline
Cyclopropylmescaline
Difluoromescaline
Difluoroescaline
Escaline
Fluoroproscaline
Isobuscaline
Isoproscaline
Jimscaline
Mescaline
Metaescaline
Methallylescaline
Proscaline
Thioproscaline
Trifluoroescaline
Trifluoromescaline
TMAs
TMA
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
Others
2C-B-BUTTERFLY
2C-B-DragonFLY
2C-B-DragonFLY-NBOH
2C-B-FLY-NB2EtO5Cl
2CB-5-hemifly
2CB-Ind
2CD-5EtO
2-TOET
5-TOET
2-TOM
5-TOM
BOB
BOD
βk-2C-B
βk-2C-I
DESOXY
DMCPA
DMBMPP
DOB-FLY
Fenfluramine
Ganesha
Macromerine
MMA
TCB-2
TOMSO
Piperazines
2C-B-PP
BZP
pFPP
Tryptaminesalpha-alkyltryptamines
4,5-DHP-α-MT
5-MeO-α-ET
5-MeO-α-MT
α-ET
α-MT
x-DALT
(Daltocin) 4-HO-DALT
(Daltacetin) 4-AcO-DALT
5-MeO-DALT
DALT
x-DET
(Ethacetin) 4-AcO-DET
(Ethocin) 4-HO-DET
5-MeO-DET
(T-9) DET
(Ethocybin) 4-PO-DET
x-DiPT
(Ipracetin) 4-AcO-DiPT
(Iprocin) 4-HO-DiPT
5-MeO-DiPT
DiPT
x-DMT
4,5-DHP-DMT
2,N,N-TMT
4-AcO-DMT
4-HO-5-MeO-DMT
4,N,N-TMT
4-Propionyloxy-DMT
5,6-diBr-DMT
5-AcO-DMT
5-Bromo-DMT
5-MeO-2,N,N-TMT
5-MeO-4,N,N-TMT
5-MeO-α,N,N-TMT
5-MeO-DMT
5-N,N-TMT
7,N,N-TMT
α,N,N-TMT
(Bufotenin) 5-HO-DMT
DMT
Norbaeocystin
(Psilocin) 4-HO-DMT
(Psilocybin) 4-PO-DMT
x-DPT
(Depracetin) 4-AcO-DPT
(Deprocin) 4-HO-DPT
5-MeO-DPT
(The Light) DPT
Ibogaine-related
18-MAC
18-MC
Coronaridine
Ibogaine
Ibogamine
ME-18-MC
Noribogaine
Tabernanthine
Voacangine
x-MET
(Metocin) 4-HO-MET
(Metocetin) 4-AcO-MET
5-MeO-MET
MET
x-MiPT
(Mipracetin) 4-AcO-MiPT
(Miprocin) 4-HO-MiPT
5-Me-MiPT
(Moxy) 5-MeO-MiPT
MiPT
Others
4-HO-DBT
4-HO-EPT
4-HO-McPT
(Lucigenol) 4-HO-MPMI
(Meprocin) 4-HO-MPT
5-MeO-EiPT
5-MeO-MALT
5-MeO-MPMI
Aeruginascin
Baeocystin
DBT
DCPT
EiPT
EPT
MPT
PiPT
Others
AL-38022A
ALPHA
Dimemebfe
Efavirenz
Glaucine
Lorcaserin
M-ALPHA
RH-34Also empathogens in general (e. g.: 5-APB, 5-MAPB, 6-APB and other substituted benzofurans).
Dissociatives(NMDARantagonists)Arylcyclo‐hexylaminesKetamine-related
2-Fluorodeschloroketamine
Arketamine ((R)-ketamine)
Deschloroketamine
Ethketamine (N-Ethylnorketamine)
Esketamine ((S)-ketamine)
Ketamine
Methoxetamine
Methoxmetamine
Methoxyketamine
MXiPr
Norketamine
Tiletamine
PCP-related
2'-Oxo-PCE
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
BDPC
Dieticyclidine (PCDE)
Eticyclidine (PCE)
PCPr
Phencyclidine (PCP)
Rolicyclidine (PCPy)
Tenocyclidine (TCP)
Others
BTCP
Gacyclidine
PRE-084
Diarylethylamines
Diphenidine
Ephenidine
Fluorolintane
Methoxphenidine
Morphinans
Dextrallorphan
Dextromethorphan
Dextrorphan
Racemethorphan
Racemorphan
Others
2-EMSB
2-MDP
8A-PDHQ
Aptiganel
Budipine
Delucemine
Dexoxadrol
Dizocilpine
Etoxadrol
Herkinorin
Ibogaine
Midafotel
NEFA
Neramexane
Nitrous oxide
Noribogaine
Perzinfotel
RB-64
Remacemide
Selfotel
Xenon
Deliriants(mAChRantagonists)
Atropine
Benactyzine
Benzatropine
Benzydamine
Biperiden
BRN-1484501
Brompheniramine
BZ
CAR-226,086
CAR-301,060
CAR-302,196
CAR-302,282
CAR-302,368
CAR-302,537
CAR-302,668
Chloropyramine
Chlorphenamine
Clemastine
CS-27349
Cyclizine
Cyproheptadine
Dicycloverine
Dimenhydrinate
Diphenhydramine
Ditran
Doxylamine
EA-3167
EA-3443
EA-3580
EA-3834
Elemicin
Flavoxate
Hyoscyamine
JB-318
JB-336
Meclozine
Mepyramine
Myristicin
Orphenadrine
Oxybutynin
Pheniramine
Phenyltoloxamine
Procyclidine
Promethazine
Scopolamine
Tolterodine
Trihexyphenidyl
Tripelennamine
Triprolidine
WIN-2299
OthersCannabinoids(CB1 agonists)Natural
Salvinorin A
THC (Dronabinol)
THCV
SyntheticAM-x
AM-087
AM-251
AM-279
AM-281
AM-356
AM-374
AM-381
AM-404
AM-411
AM-630
AM-661
AM-678
AM-679
AM-694
AM-735
AM-855
AM-881
AM-883
AM-905
AM-906
AM-919
AM-926
AM-938
AM-1116
AM-1172
AM-1220
AM-1221
AM-1235
AM-1241
AM-1248
AM-1710
AM-1714
AM-1902
AM-2201
AM-2212
AM-2213
AM-2232
AM-2233
AM-2389
AM-3102
AM-4030
AM-4054
AM-4056
AM-4113
AM-6545
CP x
CP 47,497
CP 55,244
CP 55,940
(±)-CP 55,940
(+)-CP 55,940
(-)-CP 55,940
HU-x
HU-210
HU-211
HU-239
HU-243
HU-308
HU-320
HU-331
HU-336
HU-345
JWH-x
JWH-007
JWH-015
JWH-018
JWH-019
JWH-030
JWH-047
JWH-048
JWH-051
JWH-057
JWH-073
JWH-081
JWH-098
JWH-116
JWH-120
JWH-122
JWH-133
JWH-139
JWH-147
JWH-148
JWH-149
JWH-149
JWH-161
JWH-164
JWH-166
JWH-167
JWH-171
JWH-175
JWH-176
JWH-181
JWH-182
JWH-184
JWH-185
JWH-192
JWH-193
JWH-194
JWH-195
JWH-196
JWH-197
JWH-198
JWH-199
JWH-200
JWH-203
JWH-205
JWH-210
JWH-210
JWH-213
JWH-220
JWH-229
JWH-234
JWH-249
JWH-250
JWH-251
JWH-253
JWH-258
JWH-300
JWH-302
JWH-307
JWH-336
JWH-350
JWH-359
JWH-387
JWH-398
JWH-424
Misc. designer cannabinoids
4-HTMPIPO
5F-AB-FUPPYCA
5F-AB-PINACA
5F-ADB
5F-ADB-PINACA
5F-ADBICA
5F-AMB
5F-APINACA
5F-CUMYL-PINACA
5F-NNE1
5F-PB-22
5F-SDB-006
A-796,260
A-836,339
AB-001
AB-005
AB-CHFUPYCA
AB-CHMINACA
AB-FUBINACA
AB-PINACA
ADAMANTYL-THPINACA
ADB-CHMINACA
ADB-FUBINACA
ADB-PINACA
ADBICA
ADSB-FUB-187
AMB-FUBINACA
APICA
APINACA
APP-FUBINACA
CB-13
CUMYL-PICA
CUMYL-PINACA
CUMYL-THPINACA
DMHP
EAM-2201
FAB-144
FDU-PB-22
FUB-144
FUB-APINACA
FUB-JWH-018
FUB-PB-22
FUBIMINA
JTE 7-31
JTE-907
Levonantradol
MDMB-CHMICA
MDMB-CHMINACA
MDMB-FUBINACA
MEPIRAPIM
MAM-2201
MDA-19
MN-18
MN-25
NESS-0327
NESS-040C5
Nabilone
Nabitan
NM-2201
NNE1
Org 28611
Parahexyl
PTI-1
PTI-2
PX-1
PX-2
PX-3
QUCHIC
QUPIC
RCS-4
RCS-8
SDB-005
SDB-006
STS-135
THC-O-acetate
THC-O-phosphate
THJ-018
THJ-2201
UR-144
WIN 55,212-2
XLR-11
D2 agonists
Apomorphine
Aporphine
Bromocriptine
Cabergoline
Lisuride
LSD
Memantine
Nuciferine
Pergolide
Phenethylamine
Piribedil
Pramipexole
Ropinirole
Rotigotine
Salvinorin AAlso indirect D2 agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).
GABAAenhancers
CI-966
Eszopiclone
Ibotenic acid
Muscimol (Amanita muscaria)
Zaleplon
Zolpidem
Zopiclone
Inhalants(Mixed MOA)
Aliphatic hydrocarbons
Butane
Gasoline
Kerosene
Propane
Aromatic hydrocarbons
Toluene
Ethers
Diethyl ether
Enflurane
Haloalkanes
Chlorofluorocarbons
Chloroform
κOR agonists
2-EMSB
Alazocine
Bremazocine
Butorphan
Butorphanol
Cyclazocine
Cyclorphan
Cyprenorphine
Diprenorphine
Enadoline
Herkinorin
Heroin
HZ-2
Ibogaine
Ketazocine
Levallorphan
Levomethorphan
Levorphanol
LPK-26
Metazocine
Morphine
Nalbuphine
Nalmefene
Nalorphine
Noribogaine
Oxilorphan
Pentazocine
Phenazocine
Proxorphan
Racemethorphan
Racemorphan
Salvinorin A
Spiradoline
Tifluadom
U-50488
U-69,593
Xorphanol
Oneirogens
Calea zacatechichi
Silene capensis
Galantamine
Others
Glaucine
Isoaminile
Noscapine
Pukateine

showPharmacodynamics
showvteIonotropic glutamate receptor modulatorsAMPAR
Agonists: Main site agonists: 5-Fluorowillardiine
Acromelic acid (acromelate)
AMPA
BOAA
Domoic acid
Glutamate
Ibotenic acid
Proline
Quisqualic acid
Willardiine; Positive allosteric modulators: Aniracetam
BIIB-104 (PF-04958242)
Cyclothiazide
CX-516
CX-546
CX-614
Farampator (CX-691, ORG-24448)
CX-717
CX-1739
CX-1942
Diazoxide
Hydrochlorothiazide (HCTZ)
IDRA-21
LY-392098
LY-395153
LY-404187
LY-451646
LY-503430
Mibampator (LY-451395)
Nooglutyl
ORG-26576
Oxiracetam
PEPA
Piracetam
Pramiracetam
S-18986
Tulrampator (S-47445, CX-1632)
Antagonists: ACEA-1011
ATPO
Becampanel
Caroverine
CNQX
Dasolampanel
DNQX
Fanapanel (MPQX)
GAMS
Kaitocephalin
Kynurenic acid
Kynurenine
Licostinel (ACEA-1021)
NBQX
PNQX
Selurampanel
Tezampanel
Theanine
Topiramate
YM90K
Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Cyclopropane
Enflurane
Ethanol (alcohol)
Evans blue
GYKI-52466
GYKI-53655
Halothane
Irampanel
Isoflurane
Perampanel
Pregnenolone sulfate
Sevoflurane
Talampanel; Unknown/unsorted antagonists: Minocycline
KAR
Agonists: Main site agonists: 5-Bromowillardiine
5-Iodowillardiine
Acromelic acid (acromelate)
AMPA
ATPA
Domoic acid
Glutamate
Ibotenic acid
Kainic acid
LY-339434
Proline
Quisqualic acid
SYM-2081; Positive allosteric modulators: Cyclothiazide
Diazoxide
Enflurane
Halothane
Isoflurane
Antagonists: ACEA-1011
CNQX
Dasolampanel
DNQX
GAMS
Kaitocephalin
Kynurenic acid
Licostinel (ACEA-1021)
LY-382884
NBQX
NS102
Selurampanel
Tezampanel
Theanine
Topiramate
UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Enflurane
Ethanol (alcohol)
Evans blue
NS-3763
Pregnenolone sulfate
NMDAR
Agonists: Main site agonists: AMAA
Aspartate
Glutamate
Homocysteic acid (L-HCA)
Homoquinolinic acid
Ibotenic acid
NMDA
Proline
Quinolinic acid
Tetrazolylglycine
Theanine; Glycine site agonists: β-Fluoro-D-alanine
ACBD
ACC (ACPC)
ACPD
AK-51
Apimostinel (NRX-1074)
B6B21
CCG
D-Alanine
D-Cycloserine
D-Serine
DHPG
Dimethylglycine
Glycine
HA-966
L-687414
L-Alanine
L-Serine
Milacemide
Neboglamine (nebostinel)
Rapastinel (GLYX-13)
Sarcosine; Polyamine site agonists: Neomycin
Spermidine
Spermine; Other positive allosteric modulators: 24S-Hydroxycholesterol
DHEA (prasterone)
DHEA sulfate (prasterone sulfate)
Epipregnanolone sulfate
Plazinemdor
Pregnenolone sulfate
SAGE-201
SAGE-301
SAGE-718
Antagonists: Competitive antagonists: AP5 (APV)
AP7
CGP-37849
CGP-39551
CGP-39653
CGP-40116
CGS-19755
CPP
Kaitocephalin
LY-233053
LY-235959
LY-274614
MDL-100453
Midafotel (d-CPPene)
NPC-12626
NPC-17742
PBPD
PEAQX
Perzinfotel
PPDA
SDZ-220581
Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
5,7-DCKA
7-CKA
ACC
ACEA-1011
ACEA-1328
Apimostinel (NRX-1074)
AV-101
Carisoprodol
CGP-39653
CNQX
D-Cycloserine
DNQX
Felbamate
Gavestinel
GV-196771
Harkoseride
Kynurenic acid
Kynurenine
L-689560
L-701324
Licostinel (ACEA-1021)
LU-73068
MDL-105519
Meprobamate
MRZ 2/576
PNQX
Rapastinel (GLYX-13)
ZD-9379; Polyamine site antagonists: Arcaine
Co 101676
Diaminopropane
Diethylenetriamine
Huperzine A
Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
8A-PDHQ
18-MC
α-Endopsychosin
Alaproclate
Alazocine (SKF-10047)
Amantadine
Aptiganel
Argiotoxin-636
Arketamine
ARL-12495
ARL-15896-AR
ARL-16247
Budipine
Coronaridine
Delucemine (NPS-1506)
Dexoxadrol
Dextrallorphan
Dextromethadone
Dextromethorphan
Dextrorphan
Dieticyclidine
Diphenidine
Dizocilpine
Ephenidine
Esketamine
Etoxadrol
Eticyclidine
Fluorolintane
Gacyclidine
Ibogaine
Ibogamine
Indantadol
Ketamine
Ketobemidone
Lanicemine
Levomethadone
Levomethorphan
Levomilnacipran
Levorphanol
Loperamide
Memantine
Methadone
Methorphan
Methoxetamine
Methoxphenidine
Milnacipran
Morphanol
NEFA
Neramexane
Nitromemantine
Noribogaine
Norketamine
Orphenadrine
PCPr
PD-137889
Pethidine (meperidine)
Phencyclamine
Phencyclidine
Propoxyphene
Remacemide
Rhynchophylline
Rimantadine
Rolicyclidine
Sabeluzole
Tabernanthine
Tenocyclidine
Tiletamine
Tramadol; Ifenprodil (NR2B) site antagonists:
Besonprodil
Buphenine (nylidrin)
CO-101244 (PD-174494)
Eliprodil
Haloperidol
Isoxsuprine
Radiprodil (RGH-896)
Rislenemdaz (CERC-301, MK-0657)
Ro 8-4304
Ro 25-6981
Safaprodil
Traxoprodil (CP-101606); NR2A-selective antagonists: MPX-004
MPX-007
TCN-201
TCN-213; Cations: Hydrogen
Magnesium
Zinc; Alcohols/volatile anesthetics/related: Benzene
Butane
Chloroform
Cyclopropane
Desflurane
Diethyl ether
Enflurane
Ethanol (alcohol)
Halothane
Hexanol
Isoflurane
Methoxyflurane
Nitrous oxide
Octanol
Sevoflurane
Toluene
Trichloroethane
Trichloroethanol
Trichloroethylene
Urethane
Xenon
Xylene; Unknown/unsorted antagonists: ARR-15896
Bumetanide
Caroverine
Conantokin
D-αAA
Dexanabinol
Flufenamic acid
Flupirtine
FPL-12495
FR-115427
Furosemide
Hodgkinsine
Ipenoxazone (MLV-6976)
MDL-27266
Metaphit
Minocycline
MPEP
Niflumic acid
Pentamidine
Pentamidine isethionate
Piretanide
Psychotridine
Transcrocetin (saffron)
Unsorted: Allosteric modulators: AGN-241751

See also: Receptor/signaling modulators
Metabotropic glutamate receptor modulators
Glutamate metabolism/transport modulators

showvteMonoamine reuptake inhibitorsDAT(DRIs)
Piperazines: DBL-583
GBR-12783
GBR-12935
GBR-13069
GBR-13098
Nefazodone
Vanoxerine

Piperidines: 4-Fluoropethidine
Benocyclidine (BTCP)
Desoxypipradrol
Dexmethylphenidate
Difemetorex
Ethylphenidate
HDMP-28
Methylphenidate
Pethidine (meperidine)
Phencyclidine
Pipradrol
Serdexmethylphenidate
Tenocyclidine

Pyrrolidines: Diphenylprolinol
MDPV
Naphyrone
Prolintane
Pyrovalerone

Tropanes: Altropane
Benzatropine (benztropine)
Brasofensine
CFT
Cocaine
Dichloropane
Difluoropine
Etybenzatropine (ethybenztropine)
FE-β-CPPIT
FP-β-CPPIT
Ioflupane (123I)
RTI-55
RTI-112
RTI-113
RTI-121
RTI-126
RTI-150
RTI-177
RTI-229
RTI-336
Tesofensine
Troparil
Tropoxane
WF-11
WF-23
WF-31
WF-33

Others: Adrafinil
Amifitadine
Armodafinil
Amfonelic acid
Amineptine
Ansofaxine
BTQ
BTS 74,398
Bupropion
Chaenomeles speciosa
Ciclazindol
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
Dimethocaine
Diphenylpyraline
Dizocilpine (MK-801)
DOV-102,677
DOV-216,303
Efavirenz
Ephenidine
Esketamine
EXP-561
Fencamfamin
Fezolamine
Fluorenol
GYKI-52895
Indatraline
Ketamine
Lefetamine
Levophacetoperane
Liafensine
LR-5182
Manifaxine
Mazindol
Medifoxamine
Mesocarb
Metaphit
MIN-117 (WF-516)
Modafinil
Nefopam
Nomifensine
NS-2359
O-2172
Oroxylin A
Perafensine
Pridefine
Radafaxine
Rimcazole
Sertraline
Sibutramine
Solriamfetol
Tametraline
Tedatioxetine
Tripelennamine
Venlafaxine
NET(NRIs)
Selective norepinephrine reuptake inhibitors: Amedalin
Alseroxylon
Ciclazindol
Daledalin
Edivoxetine
Esreboxetine
Lortalamine
Mazindol
Nisoxetine
Reboxetine
Talopram
Talsupram
Tandamine
Teniloxazine
Viloxazine

Norepinephrine–dopamine reuptake inhibitors: Amineptine
Bupropion
Fencamine
Fencamfamin
Hydroxybupropion
Lefetamine
Levophacetoperane
LR-5182
Manifaxine
Methylphenidate
Nomifensine
O-2172
Radafaxine
Serdexmethylphenidate
Solriamfetol

Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
CP-39,332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN5652
Milnacipran
N-Methyl-PPPA
Nafenodone
PPPA
Tofenacin
Venlafaxine

Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)

Tricyclic antidepressants: Amitriptyline
Butriptyline
Cianopramine
Clomipramine
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Melitracen
Nortriptyline
Protriptyline
Trimipramine

Tetracyclic antidepressants: Amoxapine
Maprotiline
Mianserin
Oxaprotiline
Setiptiline

Others: Antihistamines (e.g., brompheniramine, chlorphenamine, pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., ketamine, phencyclidine)
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g., desmetramadol, methadone, pethidine (meperidine), tapentadol, tramadol, levorphanol)
SERT(SRIs)
Selective serotonin reuptake inhibitors: 6-Nitroquipazine
Alaproclate
Centpropazine
Cericlamine
Citalopram
Dapoxetine
Desmethylcitalopram
Didesmethylcitalopram
Escitalopram
Femoxetine
Fluoxetine
Fluvoxamine
Indalpine
Ifoxetine
Norfluoxetine
Omiloxetine
Panuramine
Paroxetine
PIM-35
Pirandamine
RTI-353
Seproxetine
Sertraline
Zimelidine
Selective serotonin reuptake inhibitors and serotonin receptor modulators: Etoperidone
Litoxetine
Lubazodone
LY-393558
Quipazine
SB-649915
TGBA01AD
Trazodone
Vilazodone
Vortioxetine

Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
Bicifadine
CP-39332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN5652
Milnacipran
N-Methyl-PPPA
PPPA
Tofenacin
Venlafaxine

Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)

Tricyclic antidepressants: Amitriptyline
Cianopramine
Clomipramine
Cyanodothiepin
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Nortriptyline
Pipofezine
Protriptyline

Others: A-80426
Amoxapine
Antihistamines (e.g., brompheniramine, chlorphenamine, dimenhydrinate, diphenhydramine, mepyramine (pyrilamine), pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., 3-MeO-PCP, esketamine, ketamine, methoxetamine, phencyclidine)
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Hypidone
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g., dextropropoxyphene, methadone, pethidine (meperidine), levorphanol, tapentadol, tramadol)
Roxindole
VMATs
Amiodarone
Amphetamines (e.g., amphetamine, methamphetamine, MDMA)
APP
AZIK
Bietaserpine
Deserpidine
Deutetrabenazine
Dihydrotetrabenazine
Efavirenz
GBR-12935
GZ-793A
Ibogaine
Ketanserin
Lobeline
Methoxytetrabenazine
Reserpine
Rose bengal
Tetrabenazine
Valbenazine
Vanoxerine (GBR-12909)
Others
DAT enhancers: Luteolin
DAT modulators: Agonist-like: SoRI-9804
SoRI-20040; Antagonist-like: SoRI-20041
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
showvteNicotinic acetylcholine receptor modulatorsnAChRsAgonists(and PAMs)
5-HIAA
6-Chloronicotine
A-84,543
A-366,833
A-582,941
A-867,744
ABT-202
ABT-418
ABT-560
ABT-894
Acetylcholine
Altinicline
Anabasine
Anatabine
Anatoxin-a
AR-R17779
Bephenium hydroxynaphthoate
Butinoline
Butyrylcholine
Carbachol
Choline
Cotinine
Cytisine
Decamethonium
Desformylflustrabromine
Dianicline
Dimethylphenylpiperazinium
Epibatidine
Epiboxidine
Ethanol (alcohol)
Ethoxysebacylcholine
EVP-4473
EVP-6124
Galantamine
GTS-21
Ispronicline
Ivermectin
JNJ-39393406
Levamisole
Lobeline
MEM-63,908 (RG-3487)
Morantel
Nicotine (tobacco)
NS-1738
PHA-543,613
PHA-709,829
PNU-120,596
PNU-282,987
Pozanicline
Pyrantel
Rivanicline
RJR-2429
Sazetidine A
SB-206553
Sebacylcholine
SIB-1508Y
SIB-1553A
SSR-180,711
Suberyldicholine
Suxamethonium (succinylcholine)
Suxethonium (succinyldicholine)
TC-1698
TC-1734
TC-1827
TC-2216
TC-5214
TC-5619
TC-6683
Tebanicline
Tribendimidine
Tropisetron
UB-165
Varenicline
WAY-317,538
XY-4083
Antagonists(and NAMs)
18-MAC
18-MC
α-Neurotoxins (e.g., α-bungarotoxin, α-cobratoxin, α-conotoxin, many others)
ABT-126
Alcuronium
Allopregnanolone
Amantadine
Anatruxonium
AQW051
Atracurium
Barbiturates (e.g., pentobarbital, sodium thiopental)
BNC-210
Bungarotoxins (e.g., α-bungarotoxin, κ-bungarotoxin)
Bupropion
BW284C51
BW-A444
Candocuronium iodide (chandonium iodide)
Chlorisondamine
Cisatracurium
Coclaurine
Coronaridine
Curare
Cyclopropane
Dacuronium bromide
Decamethonium
Dehydronorketamine
Desflurane
Dextromethorphan
Dextropropoxyphene
Dextrorphan
Diadonium
DHβE
Dihydrochandonium
Dimethyltubocurarine (metocurine)
Dioscorine
Dipyrandium
Dizocilpine (MK-801)
Doxacurium
Encenicline
Enflurane
Erythravine
Esketamine
Fazadinium
Gallamine
Gantacurium chloride
Halothane
Hexafluronium
Hexamethonium (benzohexonium)
Hydroxybupropion
Hydroxynorketamine
Ibogaine
Isoflurane
Ketamine
Kynurenic acid
Laudanosine
Laudexium (laudolissin)
Levacetylmethadol
Levomethadone
Malouetine
ME-18-MC
Mecamylamine
Memantine
Methadone
Methorphan (racemethorphan)
Methyllycaconitine
Metocurine
Mivacurium
Morphanol (racemorphan)
Neramexane
Nitrous oxide
Norketamine
Pancuronium bromide
Pempidine
Pentamine
Pentolinium
Phencyclidine
Pipecuronium bromide
Progesterone
Promegestone
Radafaxine
Rapacuronium bromide
Reboxetine
Rocuronium bromide
Sevoflurane
Stercuronium iodide
Surugatoxin
Thiocolchicoside
Toxiferine
Tramadol
Trimetaphan camsilate (trimethaphan camsylate)
Tropeinium
Tubocurarine
Vanoxerine
Vecuronium bromide
Xenon
Precursors(and prodrugs)
Acetyl-coA
Adafenoxate
Choline (lecithin)
Citicoline
Cyprodenate
Dimethylethanolamine
Glycerophosphocholine
Meclofenoxate (centrophenoxine)
Phosphatidylcholine
Phosphatidylethanolamine
Phosphorylcholine
Pirisudanol
See also: Receptor/signaling modulators • Muscarinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators
showvteOpioid receptor modulatorsMOR
Agonists (abridged; see here for a full list): 3-HO-PCP
7-Acetoxymitragynine
7-Hydroxymitragynine
ψ-Akuammigine
α-Chlornaltrexamine
α-Narcotine
Acetyldihydrocodeine
Acetylfentanyl
Acrylfentanyl
Adrenorphin (metorphamide)
AH-7921
Akuammicine
Akuammidine
Alfentanil
Anileridine
Apparicine
β-Endorphin
BAM-12P
BAM-18P
BAM-22P
Benzhydrocodone
Benzylmorphine
Bezitramide
Biphalin
BU08070
Buprenorphine
Butorphan
Butorphanol
Butyrfentanyl
BW373U86
Carfentanil
Casokefamide
Cebranopadol
Chloroxymorphamine
Codeine
DADLE
DAMGO (DAGO)
Dermorphin
Desmetramadol (desmethyltramadol)
Desomorphine
Dextromoramide
Dextropropoxyphene (propoxyphene)
Dezocine
Dimenoxadol
Dimethylaminopivalophenone
Eluxadoline
Diamorphine (heroin)
Dihydrocodeine
Dihydroetorphine
Dihydromorphine
Dinalbuphine sebacate
Diphenoxylate
Dipipanone
Dynorphin A
Embutramide
Endomorphin-1
Endomorphin-2
Eseroline
Ethylmorphine
Etorphine
Fentanyl
Fluorophen
Frakefamide
Furanylfentanyl
Hemorphin-4
Herkinorin
Hodgkinsine
Hydrocodone
Hydromorphinol
Hydromorphone
IBNtxA
Ketamine
Ketobemidone
Kratom
Laudanosine
Lefetamine
Leu-enkephalin
Levacetylmethadol
Levomethorphan
Levorphanol
Lexanopadol
Loperamide
Loxicodegol
LS-115509
Matrine
Meptazinol
Met-enkephalin (metenkefalin)
Methadone
Metkefamide
Metopon
Mitragynine
Mitragynine pseudoindoxyl
Morphiceptin
Morphine
Nalbuphine
NalBzOH
Nalmexone
Naltalimide
Neopine
NFEPP
Nicocodeine
Nicodicodine
Nicomorphine
NKTR-181
Norketamine
Nufenoxole
Octreotide
Oliceridine
OM-3-MNZ
Oripavine
Oxycodone
Oxymorphazone
Oxymorphonazine
Oxymorphone
Oxymorphone phenylhydrazone
OxyPNPH
Papaver somniferum (opium)
Pentazocine
Pericine
Pethidine (meperidine)
Phenazocine
Phencyclidine
Piminodine
Piritramide
PL-017
Prodine
Propiram
PZM21
Racemethorphan
Racemorphan
Remifentanil
Salsolinol
SC-17599
Sinomenine
Sufentanil
Tapentadol
Tetrahydropapaveroline
TH-030418
Thebaine
Thienorphine
Tianeptine
Tilidine
Tramadol
Trimebutine
TRIMU 5
TRV734
Tubotaiwine
U-47700
Valorphin
Viminol
Xorphanol
PAMs: BMS-986121
BMS-986122
Antagonists: (3S,4S)-Picenadol
2-(S)-N,N-(R)-Viminol
3CS-nalmefene
4-Caffeoyl-1,5-quinide
4′-Hydroxyflavanone
4',7-Dihydroxyflavone
6β-Naltrexol
6β-Naltrexol-d4
18-MC
α-Gliadin
β-Chlornaltrexamine
β-Funaltrexamine
Akuammine
Alvimopan
AM-251
Apigenin
AT-076
Axelopran
Bevenopran
Catechin
Catechin gallate
Clocinnamox
CTAP
CTOP
Cyclofoxy
Cyprodime
Diacetylnalorphine
Diprenorphine
ECG
EGC
Epicatechin
Eptazocine
Gemazocine
Ginsenoside R
Hyperoside
Ibogaine
JDTic
Levallorphan
Lobeline
LY-255582
LY-2196044
Methocinnamox
Methylnaltrexone
Methylsamidorphan chloride
Naldemedine
Nalmefene
Nalodeine (N-allylnorcodeine)
Nalorphine
Nalorphine dinicotinate
Naloxazone
Naloxegol
Naloxol
Naloxonazine
Naloxone
Naltrexazone
Naltrexonazine
Naltrexone
Naltrindole
Naringenin
Noribogaine
Oxilorphan
Pawhuskin A
Rimonabant
Quadazocine
Samidorphan
Taxifolin
Unknown/unsorted: Cannabidiol
Coronaridine
Cyproterone acetate
Dihydroakuuamine
Tabernanthine
Tetrahydrocannabinol
DOR
Agonists: 3CS-nalmefene
6'-GNTI
7-SIOM
ADL-5747 (PF-04856881)
ADL-5859
Alazocine (SKF-10047)
Amoxapine
AR-M100390 (ARM390)
AZD2327
β-Endorphin
BAM-18P
Biphalin
BU-48
Butorphan
Butorphanol
BW373U86
Casokefamide
Cebranopadol
Codeine
Cyclazocine
DADLE
Deltorphin A
Deltorphin I
Deltorphin II
Desmethylclozapine
Desmetramadol (desmethyltramadol)
Dezocine
Diamorphine (heroin)
Dihydroetorphine
Dihydromorphine
DPDPE
DPI-221
DPI-3290
DSLET
Ethylketazocine
Etorphine
Fentanyl
FIT
Fluorophen
Hemorphin-4
Hydrocodone
Hydromorphone
Ibogaine
Isomethadone
JNJ-20788560
KNT-127
Kratom
Laudanosine
Leu-enkephalin
Levomethorphan
Levorphanol
Lexanopadol
Lofentanil
Met-enkephalin (metenkefalin)
Metazocine
Metkefamide
Mitragynine
Mitragynine pseudoindoxyl
Morphine
N-Phenethyl-14-ethoxymetopon
Norbuprenorphine
NalBzOH
Oripavine
Oxycodone
Oxymorphone
Pethidine (meperidine)
Proglumide
Racemethorphan
Racemorphan
RWJ-394674
Samidorphan
SB-235863
SNC-80
SNC-162
TAN-67 (SB-205,607)
TH-030418
Thebaine
Thiobromadol (C-8813)
Tonazocine
Tramadol
TRV250
Xorphanol
Zenazocine
Antagonists: 4',7-Dihydroxyflavone
5'-NTII
6β-Naltrexol
6β-Naltrexol-d4
α-Santolol
β-Chlornaltrexamine
Apigenin
AT-076
Axelopran
Bevenopran
BNTX
Catechin
Catechin gallate
Clocinnamox
Diacetylnalorphine
Diprenorphine
ECG
EGC
Eluxadoline
Epicatechin
ICI-154129
ICI-174864
LY-255582
LY-2196044
Methylnaltrexone
Methylnaltrindole
N-Benzylnaltrindole
Nalmefene
Nalorphine
Naltrexone
Naltriben
Naltrindole
Naloxone
Naringenin
Noribogaine
Pawhuskin A
Quadazocine
SDM25N
SoRI-9409
Taxifolin
Thienorphine
Unknown/unsorted: 18-MC
Cannabidiol
Coronaridine
Cyproterone acetate
Tabernanthine
Tetrahydrocannabinol
KOR
Agonists: 3CS-nalmefene
6'-GNTI
8-CAC
18-MC
14-Methoxymetopon
β-Chlornaltrexamine
β-Funaltrexamine
Adrenorphin (metorphamide)
Akuuamicine
Alazocine (SKF-10047)
Allomatrine
Apadoline
Asimadoline
BAM-12P
BAM-18P
BAM-22P
Big dynorphin
Bremazocine
BRL-52537
Butorphan
Butorphanol
BW373U86
Cebranopadol
Ciprefadol
CR665
Cyclazocine
Cyclorphan
Cyprenorphine
Desmetramadol (desmethyltramadol)
Diamorphine (heroin)
Diacetylnalorphine
Difelikefalin
Dihydroetorphine
Dihydromorphine
Dinalbuphine sebacate
Diprenorphine
Dynorphin A
Dynorphin B (rimorphin)
Eluxadoline
Enadoline
Eptazocine
Erinacine E
Ethylketazocine
Etorphine
Fedotozine
Fentanyl
Gemazocine
GR-89696
GR-103545
Hemorphin-4
Herkinorin
HS665
Hydromorphone
HZ-2
Ibogaine
ICI-199,441
ICI-204,448
Ketamine
Ketazocine
Laudanosine
Leumorphin (dynorphin B-29)
Levallorphan
Levomethorphan
Levorphanol
Lexanopadol
Lofentanil
LPK-26
Lufuradom
Matrine
MB-1C-OH
Menthol
Metazocine
Metkefamide
Mianserin
Mirtazapine
Morphine
Moxazocine
MR-2034
N-MPPP
Nalbuphine
NalBzOH
Nalfurafine
Nalmefene
Nalodeine (N-allylnorcodeine)
Nalorphine
Naltriben
Niravoline
Norbuprenorphine
Norbuprenorphine-3-glucuronide
Noribogaine
Norketamine
Oripavine
Oxilorphan
Oxycodone
Pentazocine
Pethidine (meperidine)
Phenazocine
Proxorphan
Racemethorphan
Racemorphan
RB-64
Salvinorin A (salvia)
Salvinorin B ethoxymethyl ether
Salvinorin B methoxymethyl ether
Samidorphan
Spiradoline (U-62,066)
TH-030418
Thienorphine
Tifluadom
Tricyclic antidepressants (e.g., amitriptyline, desipramine, imipramine, nortriptyline)
U-50488
U-54,494A
U-69,593
Xorphanol
Antagonists: 4′-Hydroxyflavanone
4',7-Dihydroxyflavone
5'-GNTI
6'-GNTI
6β-Naltrexol
6β-Naltrexol-d4
β-Chlornaltrexamine
Buprenorphine/samidorphan
Amentoflavone
ANTI
Apigenin
Arodyne
AT-076
Aticaprant
Axelopran
AZ-MTAB
Binaltorphimine
BU09059
Buprenorphine
Catechin
Catechin gallate
CERC-501 (LY-2456302)
Clocinnamox
Cyclofoxy
Dezocine
DIPPA
EGC
ECG
Epicatechin
Hyperoside
JDTic
LY-255582
LY-2196044
LY-2444296
LY-2459989
LY-2795050
MeJDTic
Methylnaltrexone
ML190
ML350
MR-2266
N-Fluoropropyl-JDTic
Naloxone
Naltrexone
Naltrindole
Naringenin
Norbinaltorphimine
Noribogaine
Pawhuskin A
PF-4455242
RB-64
Quadazocine
Taxifolin
UPHIT
Zyklophin
Unknown/unsorted: Akuammicine
Akuammine
Coronaridine
Cyproterone acetate
Dihydroakuuamine
Ibogamine
Tabernanthine
NOP
Agonists: (Arg14,Lys15)Nociceptin
((pF)Phe4)Nociceptin(1-13)NH2
(Phe1Ψ(CH2-NH)Gly2)Nociceptin(1-13)NH2
Ac-RYYRWK-NH2
Ac-RYYRIK-NH2
BU08070
Buprenorphine
Cebranopadol
Dihydroetorphine
Etorphine
JNJ-19385899
Levomethorphan
Levorphanol
Lexanopadol
MCOPPB
MT-7716
NNC 63-0532
Nociceptin (orphanin FQ)
Nociceptin (1-11)
Nociceptin (1-13)NH2
Norbuprenorphine
Racemethorphan
Racemorphan
Ro64-6198
Ro65-6570
SCH-221510
SCH-486757
SR-8993
SR-16435
Sunobinop (S-117957)
TH-030418
Antagonists: (Nphe1)Nociceptin(1-13)NH2
AT-076
BAN-ORL-24
BTRX-246040 (LY-2940094)
J-113,397
JTC-801
NalBzOH
Nociceptin (1-7)
Nocistatin
SB-612,111
SR-16430
Thienorphine
Trap-101
UFP-101
Unsorted
β-Casomorphins
Amidorphin
BAM-20P
Cytochrophin-4
Deprolorphin
Gliadorphin (gluteomorphin)
Gluten exorphins
Hemorphins
Kava constituents
MEAGL
MEAP
NEM
Neoendorphins
Nepetalactone (catnip)
Peptide B
Peptide E
Peptide F
Peptide I
Rubiscolins
Soymorphins
Others
Enkephalinase inhibitors: Amastatin
BL-2401
Candoxatril
D -Phenylalanine
Dexecadotril (retorphan)
Ecadotril (sinorphan)
Kelatorphan
Racecadotril (acetorphan)
RB-101
RB-120
RB-3007
Opiorphan
Selank
Semax
Spinorphin
Thiorphan
Tynorphin
Ubenimex (bestatin)
Propeptides: β-Lipotropin (proendorphin)
Prodynorphin
Proenkephalin
Pronociceptin
Proopiomelanocortin (POMC)
Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)

showvteSigma receptor modulatorsσ1
Agonists: 3-PPP
4-PPBP
5-MeO-DMT
Alazocine (SKF-10047)
Amantadine
Arketamine
BD-737
BD-1052
Blarcamesine
Captodiame
Citalopram
CGRP
Cloperastine
Cocaine
Cutamesine (SA-4503)
Cyclazocine
Dehydroepiandrosterone (DHEA) (prasterone)
Dehydroepiandrosterone sulfate (DHEA-S) (prasterone sulfate)
Dextrallorphan
Dextromethorphan (DXM)
Dextrorphan (DXO)
Dimemorfan
Dimethyltryptamine (DMT)
Ditolylguanidine (DTG)
Donepezil
Eliprodil
Escitalopram
Fabomotizole (afobazole)
Fluoxetine
Fluvoxamine
Ifenprodil
Igmesine (JO-1784)
IPAB
Ketamine
L-687384
MDMA (midomafetamine)
Memantine
Methamphetamine
Methoxetamine
Methylphenidate
Nepinalone
Neuropeptide Y
Noscapine
OPC-14523
Opipramol
Pentazocine
Pentoxyverine (carbetapentane)
PRE-084
Pregnenolone
Pregnenolone sulfate
Pridopidine
Racemethorphan (methorphan)
Racemorphan (morphanol)
UMB-23
UMB-82
Antagonists: 3-PPP
AC-927
BD-1008
BD-1031
BD-1047
BD-1060
BD-1063
BD-1067
BMY-14802 (BMS-181100)
CM-156
Dup-734
E-5842
E-52862 (S1RA)
Haloperidol
LR-132
LR-172
MS-377
NE-100
NPC-16377
Panamesine (EMD-57455)
PD-144418
Pentazocine
Progesterone
Rimcazole (BW-234U)
Sertraline
SR-31742A
Allosteric modulators: Phenytoin; Positive: Methylphenylpiracetam
SOMCL-668
Unknown/unsorted: 3-Methoxydextrallorphan
3-MeO-PCP
4C-T-2
4-IBP
4-IPBS
4-MeO-PCP
5-MeO-DALT
5-MeO-DiPT
Amitriptyline
Azidopamil
Chlorpromazine
Clemastine
Clomipramine
Clorgiline
D-Deprenyl
DiPT
DPT
Ibogaine
Imipramine
KCR-12-83.1
Nemonapride
Noribogaine
RHL-033
RS-67,333
RTI-55
Saffron
Safinamide
Selegiline
Spipethiane
Trifluoperazine
W-18
YKP10A
σ2
Agonists: 3-PPP
Arketamine
BD-1047
BD1063
Ditolylguanidine (DTG)
DKR-1005
DKR-1051
Haloperidol
Ifenprodil
Ketamine
MDMA (midomafetamine)
Methamphetamine
OPC-14523
Opipramol
PB-28
Phencyclidine
Siramesine (Lu 28-179)
UKH-1114
Antagonists: AC-927
BD-1008
BD-1067
CM-156
CT-1812
LR-172
MIN-101
Panamesine (EMD-57455)
SAS-0132
Unknown/unsorted: 3-Methoxydextrallorphan
3-MeO-PCE
4-MeO-PCP
5-MeO-DALT
5-MeO-DiPT
Clemastine
DiPT
DPT
Ibogaine
Nemonapride
Nepinalone
Noribogaine
Pentazocine
RS-67,333
Safinamide
TMA
UMB-23
UMB-82
W-18
Unsorted
Agonists: Berberine
Ethylketazocine
Fourphit
Metaphit
Naluzotan
Tapentadol
Tenocyclidine
Antagonists: AHD1
AZ66
Lamotrigine
Naloxone
SM-21
UMB-100
UMB-101
UMB-103
UMB-116
YZ-011
YZ-069
YZ-185
Allosteric modulators: SKF-83959
Unknown/unsorted: 18-Methoxycoronaridine
BMY-13980
Butaclamol
Caramiphen
Carvotroline
Chlorphenamine (chlorpheniramine)
Chlorpromazine
Cinnarizine
Cinuperone
Clocapramine
Dezocine
EMD-59983
Hypericin (St. John's wort)
Fluphenazine
Gevotroline (WY-47384)
Mepyramine (pyrilamine)
Molindone
Perphenazine
Pimozide
Proadifen
Promethazine
Propranolol
Quinidine
Remoxipride
SL 82.0715
SR-31747A
Tiospirone (BMY-13859)
Venlafaxine
See also: Receptor/signaling modulators
showAuthority control National libraries
United States
Other
Faceted Application of Subject Terminology






